Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
Verona Pharma (Nasdaq: VRNA) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025. The company will host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the results and provide a corporate update.
The company specializes in developing and commercializing innovative therapies for chronic respiratory diseases. Their first commercial product, Ohtuvaire (ensifentrine), is an inhaled maintenance treatment for COPD that uniquely combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The treatment shows potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases.
Verona Pharma (Nasdaq: VRNA) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 27 febbraio 2025. L'azienda ospiterà una conference call per la comunità degli investitori alle 9:00 EST / 14:00 GMT per discutere i risultati e fornire un aggiornamento aziendale.
L'azienda si specializza nello sviluppo e nella commercializzazione di terapie innovative per le malattie respiratorie croniche. Il loro primo prodotto commerciale, Ohtuvaire (ensifentrina), è un trattamento di mantenimento inalato per la BPCO che combina in modo unico attività broncodilatatorie e anti-infiammatorie non steroidee in una sola molecola. Il trattamento mostra potenziali applicazioni nella bronchiectasia non fibrotica, nella fibrosi cistica, nell'asma e in altre malattie respiratorie.
Verona Pharma (Nasdaq: VRNA) ha programado el anuncio de los resultados financieros del cuarto trimestre y del año completo 2024 para el jueves 27 de febrero de 2025. La compañía realizará una conferencia telefónica para la comunidad inversora a las 9:00 a.m. EST / 2:00 p.m. GMT para discutir los resultados y proporcionar una actualización corporativa.
La empresa se especializa en el desarrollo y comercialización de terapias innovadoras para enfermedades respiratorias crónicas. Su primer producto comercial, Ohtuvaire (ensifentrina), es un tratamiento de mantenimiento inhalado para la EPOC que combina de manera única actividades broncodilatadoras y antiinflamatorias no esteroides en una sola molécula. El tratamiento muestra aplicaciones potenciales en la bronquiectasia no fibrocística, la fibrosis quística, el asma y otras enfermedades respiratorias.
Verona Pharma (Nasdaq: VRNA)는 2024년 4분기 및 전체 연도 재무 결과 발표를 2025년 2월 27일 목요일로 예정했습니다. 회사는 9:00 a.m. EST / 2:00 p.m. GMT에 투자자 커뮤니티를 위한 컨퍼런스 콜을 개최하여 결과를 논의하고 기업 업데이트를 제공할 예정입니다.
회사는 만성 호흡기 질환에 대한 혁신적인 치료법을 개발하고 상용화하는 전문 기업입니다. 그들의 첫 상업 제품인 Ohtuvaire (엔시펜트린)은 COPD를 위한 흡입 유지 치료제로, 독특하게 한 분자 내에서 기관지 확장제와 비스테로이드 항염증 작용을 결합합니다. 이 치료법은 비낭포성 섬유증 기관지 확장증, 낭포성 섬유증, 천식 및 기타 호흡기 질환에 대한 잠재적 적용 가능성을 보여줍니다.
Verona Pharma (Nasdaq: VRNA) a programmé l'annonce de ses résultats financiers pour le quatrième trimestre et l'année entière 2024 pour le jeudi 27 février 2025. L'entreprise organisera une conférence téléphonique pour la communauté des investisseurs à 9h00 EST / 14h00 GMT pour discuter des résultats et fournir une mise à jour sur l'entreprise.
L'entreprise se spécialise dans le développement et la commercialisation de thérapies innovantes pour les maladies respiratoires chroniques. Leur premier produit commercial, Ohtuvaire (ensifentrine), est un traitement d'entretien inhalé pour la BPCO qui combine de manière unique des activités de bronchodilatation et des actions anti-inflammatoires non stéroïdiennes dans une seule molécule. Le traitement montre des applications potentielles dans la bronchiectasie non fibrosique, la fibrose kystique, l'asthme et d'autres maladies respiratoires.
Verona Pharma (Nasdaq: VRNA) hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Donnerstag, den 27. Februar 2025, angesetzt. Das Unternehmen wird um 9:00 Uhr EST / 14:00 Uhr GMT eine Telefonkonferenz für die Investmentgemeinschaft abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Das Unternehmen ist auf die Entwicklung und Vermarktung innovativer Therapien für chronische Atemwegserkrankungen spezialisiert. Ihr erstes kommerzielles Produkt, Ohtuvaire (Ensifentrin), ist eine inhalative Erhaltungsbehandlung für COPD, die einzigartig bronchodilatatorische und nicht-steroidale entzündungshemmende Aktivitäten in einem Molekül kombiniert. Die Behandlung zeigt potenzielle Anwendungen bei nicht-zystischer Fibrose-Bronchiektasie, zystischer Fibrose, Asthma und anderen Atemwegserkrankungen.
- None.
- None.
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and ask to join the Verona Pharma call:
- +1-800-836-8184 for callers in the United States
- +1-646-357-8785 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.
For further information please contact:
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of Investor Relations and Communications | IR@veronapharma.com |
| Argot Partners US Investor Enquiries | Tel: +1-212-600-1902 verona@argotpartners.com |
| Ten Bridge Communications International / US Media Enquiries | Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com |
| Wendy Ryan |
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
FAQ
When will Verona Pharma (VRNA) report its Q4 and full year 2024 earnings?
What time is Verona Pharma's (VRNA) Q4 2024 earnings call?
What is Verona Pharma's (VRNA) main commercial product?
What medical conditions can Verona Pharma's (VRNA) ensifentrine potentially treat?
